Barriers to PARP Inhibitors Plus Androgen Receptor-Targeted Agents in Earlier Treatment Settings
By Tanya Dorff, MD - Last Updated: February 13, 2023Tanya Dorff, MD, Associate Professor in the Department of Medical Oncology & Therapeutics Research, and Section Chief of the Genitourinary Disease Program, City of Hope Comprehensive Cancer Center, shares the barriers to utilizing PARP inhibitors plus androgen receptor-targeted agents in the castration-sensitive or upfront prostate cancer settings.
View Dr. Dorff’s other comments on treatment for prostate cancer, including PROpel and MAGNITUDE Trials for mCRPC and Combination Versus Sequential Therapy for mCRPC.
Related Posts
Compared with ADT alone, apalutamide plus ADT had a favorable hazard ratio across all end points regardless of age.
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Research shed light on the safety and efficacy of pembrolizumab plus enzalutamide and ADT in patients with NHA-naïve mHSPC.
Investigators used plasma samples from the ORIOLE study to conduct a blind validation study based on this new research.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.